Although semaglutide is approved for treatment of obesity, tirzepatide and CagriSema are still in clinical trials and not yet approved for obesity
While tissue repair is the best-developed thread, the preclinical literature attaches several other systemic activities to GHK-Cu, each grounded in the same copper-handling and gene-modulating biology and each carrying the same preclinical caveat
Then we have a big aging event of our immune system
Patients who report benefit from adding glutathione during tirzepatide therapy are likely experiencing one of three things: (1) genuine oxidative stress reduction, (2) placebo effect, or (3) correction of an unrelated deficiency (poor dietary sulfur amino acid intake, inadequate sleep, overtraining)
When administered, the compound binds to both receptor types, triggering enhanced insulin secretion from pancreatic beta cells while simultaneously suppressing inappropriate glucagon release